425638-74-0

Basic information

• Product Name: 2-(2-CHLOROQUINAZOLINE-4-YL)-ACETAMIDE
• Synonyms: 2-(2-CHLOROQUINAZOLINE-4-YL)-ACETAMIDE;2-(2-chloroquinazolin-4-yl)acetaMide;2-Chloro-4-quinazolineacetamide
• CAS NO: 425638-74-0
• Molecular Formula: C10H8ClN3O
• Molecular Weight: 221.64302
• Mol File: 425638-74-0.mol

Chemical Properties

• Boiling Point: 373.077°C at 760 mmHg
• Flash Point: 179.431°C
• Appearance: /
• Density: 1.425g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.673
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-(2-CHLOROQUINAZOLINE-4-YL)-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-CHLOROQUINAZOLINE-4-YL)-ACETAMIDE(425638-74-0)
• EPA Substance Registry System: 2-(2-CHLOROQUINAZOLINE-4-YL)-ACETAMIDE(425638-74-0)

Safety Data

• Hazardous Substances Data: 425638-74-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
2-(2-CHLOROQUINAZOLINE-4-YL)-ACETAMIDE is used as a key intermediate in the synthesis of pharmaceuticals for targeting chloroquinazoline receptors, which are implicated in various biological processes and diseases. Its incorporation into drug molecules can potentially lead to the development of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(2-CHLOROQUINAZOLINE-4-YL)-ACETAMIDE serves as a versatile precursor for the creation of quinazoline-based compounds. These compounds are known for their wide range of biological activities, making them valuable in the synthesis of new organic molecules with potential applications in various industries.
Used in Drug Discovery:
2-(2-CHLOROQUINAZOLINE-4-YL)-ACETAMIDE is utilized as a starting material in drug discovery processes, where its unique structure can be leveraged to design and develop novel pharmaceuticals with specific therapeutic targets, potentially leading to the creation of innovative treatments for various medical conditions.

InChI:InChI=1/C10H8ClN3O/c11-10-13-7-4-2-1-3-6(7)8(14-10)5-9(12)15/h1-4H,5H2,(H2,12,15)

Upstream product

• 86-96-4 1,2,3,4-tetrahydro-quinazoline-2,4-dione 
• 607-68-1 2,4-dichloroquinazoline 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 425637-18-9 sotrastaurin 
• 425638-73-9 2-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-acetamide 

Relevant articles and documents

INDOLYLMALEIMIDES AS SOFT PAN-PKC INHIBITORS

The present invention relates to new kinase inhibitors, more specifically soft PKC inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new soft PKC inhibitors compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including autoimmune and inflammatory diseases.

Structure-activity relationship and pharmacokinetic studies of sotrastaurin (aeb071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis

Protein kinase C (PKC) isotypes have emerged as key targets for the blockade of early T-cell activation. Herein, we report on the structure-activity relationship and the detailed physicochemical and in vivo pharmacokinetic properties of sotrastaurin (AEB071, 1), a novel maleimide-based PKC inhibitor currently in phase II clinical trials. Most notably, the preferred uptake of sotrastaurin into lymphoid tissues is an important feature, which is likely to contribute to its in vivo efficacy.

NOVEL THIENOPYRROLE COMPOUNDS

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treati

Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4- yl]-pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes

A series of novel maleimide-based inhibitors of protein kinase C(PKC) were designed, synthesized, and evaluated. AEB071 (1) was found to be a potent, selective inhibitor of classical and novel PKC isotypes. 1 is a highly efficient immunomodulator, acting via inhibition of early T cell activation. The binding mode of maleimides to PKCs, proposed by molecular modeling, was confirmed by X-ray analysis of 1 bound in the active site of PKCα. 2009 American Chemical Society.

Indolylmaleimide derivatives

Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.